Absci to Participate in Upcoming Investor Conferences
VANCOUVER, Wash. and NEW YORK, March 26, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a data-first generative AI drug creation company, today announced the company will be participating in the following upcoming investor conferences.
- H.C. Wainwright 2nd Annual Artificial Intelligence Based Drug Discovery & Development Virtual Conference
Fireside chat on Wednesday, April 2 at 10:30 a.m. Eastern Time / 7:30 a.m. Pacific Time
- 24th Annual Needham Virtual Healthcare Conference
Fireside chat on Tuesday, April 8 at 3:45 p.m. Eastern Time / 12:45 p.m. Pacific Time
Interested parties may access live and archived webcasts of the fireside chat sessions on the company’s investor relations website at: .
About Absci
is a data-first generative AI drug creation company that combines AI with scalable wet lab technologies to create better biologics for patients, faster. Our ™ platform unlocks the potential to accelerate time to clinic and increase the probability of success by simultaneously optimizing multiple drug characteristics important to both development and therapeutic benefit. With the data to train, the AI to create, and the wet lab to validate, we can screen billions of cells per week, allowing us to go from AI-designed candidates to wet lab-validated candidates in as little as six weeks. Absci’s headquarters is in Vancouver, WA, with our AI Research Lab in New York City and an Innovation Center in Zug, Switzerland. Visit and follow us on LinkedIn (), X (Twitter) (), and .
Investor Contact
Alex Khan
VP, Finance & Investor Relations
Media Contact
